A practical reference on GW501516: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-29 and is reviewed periodically as new material appears.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Affinity purification coupled to mass spectrometry mostly detects stable interactions and thus better indicates functional in vivo PPIs. This method starts by purification of the tagged protein, which is expressed in the cell usually at in vivo concentrations, and its interacting proteins (affinity purification). One of the most advantageous and widely used methods to purify proteins with very low contaminating background is the tandem affinity purification, developed by Bertrand Seraphin and Matthias Mann and respective colleagues. PPIs can then be analysed by mass spectrometry using different methods: chemical incorporation, biological or metabolic incorporation (SILAC), and label-free methods. Furthermore, network theory has been used to study the whole set of identified protein–protein interactions in cells.
Biden also faced significant opposition from uncommitted voters and the Uncommitted National Movement in their protest vote movement against Biden due to his support for Israel during the Gaza war, which collectively won 36 delegates. Following a "disastrous" June 2024 debate performance against Trump that "inflamed age concerns", Biden ultimately withdrew from the race on July 21, 2024, and immediately endorsed Kamala Harris to replace him in his place as the party's presidential nominee. Harris quickly announced her own presidential campaign later that day and by the next day, Harris had secured the non-binding support of enough uncommitted delegates that were previously pledged to Biden to make her the party's presumptive nominee. Biden's withdrawal made him the first eligible incumbent president since Lyndon B. Johnson in 1968 not to seek re-election, and the first to withdraw after securing enough delegates to win the nomination. Harris is the first presidential nominee who did not participate in the presidential primaries since Vice President Hubert Humphrey, also in 1968, and the first since the modern Democratic Party primary procedure was created in 1972 (prior to which most states did not hold primary elections). On August 5, 2024, after five days of online balloting, Democratic National Convention delegates voted to make Harris the party's 2024 presidential nominee. She selected Minnesota Governor Tim Walz as her running mate the following day and accepted the party's nomination on August 22.
The causes of common gynecomastia remain uncertain, but are thought to result from an imbalance between the actions of estrogen, which stimulates breast tissue growth, and androgens, which inhibit breast tissue growth. Breast prominence can result from enlargement of glandular breast tissue, chest adipose tissue (fat), and skin, and is typically a combination. As in females, estrogen stimulates the growth of breast tissue in males. In addition to directly stimulating breast tissue growth, estrogens indirectly decrease secretion of testosterone by suppressing luteinizing hormone secretion, resulting in decreased testicular secretion of testosterone.
Exocrine glands secrete their products through a duct onto an outer or inner surface of the body, such as the skin or the gastrointestinal tract. Secretion is directly onto the apical surface. The glands in this group can be divided into three groups:
== Medical uses == Stanozolol has been used with some success to treat venous insufficiency. It stimulates blood fibrinolysis and has been evaluated for the treatment of the more advanced skin changes in venous disease such as lipodermatosclerosis. Several randomized trials noted improvement in the area of lipodermatosclerosis, reduced skin thickness, and possibly faster ulcer healing rates with stanozolol. It is also being studied to treat hereditary angioedema, osteoporosis, and skeletal muscle injury.
Sources: en.wikipedia.org
== Studies == Ketogenic amino acids serve important roles in the human body, leading to the study of ketogenic amino acid rich (KAAR) diets as possible treatment for non-alcoholic fatty liver disease (NAFLD) and diabetes. Dietary studies of fatty liver disease in mice show that decreasing the intake of ketogenic amino acids lysine and threonine may induce hepatic steatosis, a major cause of non-alcoholic fatty liver disease. Leucine in particular has been shown to serve an important role in the metabolic pathway for insulin via activation of the rapamycin complex 1 (mTORC1) and protein S6 kinase 1 (S6K1) for which over-activation leads to insulin resistance. Further studies illustrate that ketogenic amino acid rich diets may aid in decreasing obesity and insulin resistance, but their usage remains disputed. Ketone bodies, specifically β-hydroxybutyrate (βHB) whose levels are increased while on a ketogenic diet, aid in the renewal of myelin for demyelinated axons. This renewal of myelin is important for individuals with multiple sclerosis (MS). MS is a condition which the immune system will attack the myelin sheath that insulates the nerves. Ketogenic diets are being explored as a possible remedy for this condition as the ketone bodies aid in the regeneration of myelin. Ketogenic diets are shown to alleviate diffuse axonal injury (DAI). This was tested using rats being fed a standard diet in comparison to rats being fed a ketogenic diet post DAI.
4,500 Boers surrendered and much equipment was captured, but as with Roberts's drive against Kruger, these losses were of relatively little consequence, as the hard core of the Boer armies and their most determined and active leaders remained at large. From the Basin, Christiaan de Wet headed west. Although hounded by British columns, he succeeded in crossing the Vaal into western Transvaal, to allow Steyn to travel to meet their leaders. There was much sympathy for the Boers in Europe. In October, President Kruger and members of the Transvaal government left Portuguese East Africa on the Dutch warship De Gelderland, sent by the Queen Wilhelmina of the Netherlands. Paul Kruger's wife, however, was too ill to travel and remained in South Africa where she died on 20 July 1901 without seeing her husband again. President Kruger first went to Marseille and then to the Netherlands, where he stayed before moving to Clarens, Switzerland, where he died in exile in 1904.
The corselet, also known as a breastplate or gorget, is an oval or rectangular collar-piece resting on the shoulders, chest and back, to support the helmet and seal it to the suit, usually made from copper and brass, but occasionally steel. The helmet is usually connected to the suit by placing the holes around the rubberised collar of the suit over bolts along the rim of the corselet, and then clamping the brass straps known as brailes against the collar with wing nuts to press the rubber against the metal of the corselet rim to make a water-tight seal. An alternative method was to bolt the bonnet to the corselet over a rubber collar bonded to the top of the suit. Most six and twelve bolt bonnets are joined to the corselet by 1/8th turn interrupted thread. The helmet neck thread is placed onto the neck of the corselet facing the divers left front, where the threads do not engage, and then rotated forward, engaging the thread and seating on a leather gasket to make a watertight seal. The helmet usually has a safety lock which prevents the bonnet from rotating back and separating underwater. Other styles of connection are also used, with the joint secured by clamps or bolts (usually three).
=== Remediation of DNAPLs === Mitigation of LNAPLs tends to be less complex and require simpler engineering strategies. Conversely, DNAPLs can seep into cracks in the parent material of the subsurface, complicating both their movement and the technology required for their mitigation. In a best-case scenario, the DNAPL is continuous and has collected as a reservoir above the impermeable layer. In this scenario, a recovery well can be drilled and installed. When it comes to DNAPL remediation, the earlier it is removed, the better.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.